Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) shares shot up 13.1% on Wednesday . The company traded as high as C$3.56 and last traded at C$3.45. 5,663 shares changed hands during mid-day trading, a decline of 24% from the average session volume of 7,410 shares. The stock had previously closed at C$3.05.
Eupraxia Pharmaceuticals Stock Up 13.1 %
The business’s 50-day moving average price is C$2.78 and its 200-day moving average price is C$2.71.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc, a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis.
Featured Articles
- Five stocks we like better than Eupraxia Pharmaceuticals
- Short Selling: How to Short a Stock
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- What is Insider Trading? What You Can Learn from Insider Trading
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- Using the MarketBeat Dividend Tax Calculator
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.